No title
Background and hypothesis: KDIGO recommends proteinuria <1 g/d as a treatment target in patients with immunoglobulin A nephropathy (IgAN) because of high risk of progression to kidney failure. However, long-term kidney outcomes in patients with low-grade proteinuria remain insufficiently studied. Methods: We enrolled patients with biopsy-proven primary IgAN from the Swedish Renal Registry and anal
